Literature DB >> 29201156

Evidence-based management of Raynaud's phenomenon.

Ariane L Herrick1.   

Abstract

Raynaud's phenomenon (RP) is relevant to the rheumatologist because it may signify an underlying connective tissue disease and also because it can be very challenging to treat, especially when it has progressed to digital ulceration or critical ischaemia. This review article discusses diagnosis (does this patient have an underlying connective tissue disease?), including the role for nailfold capillaroscopy, and treatment. Management of 'uncomplicated' RP is first described and then treatment of RP complicated by progression to digital ulceration or critical ischaemia, highlighting recent advances (including phosphodiesterase type 5 inhibition, and endothelin 1 receptor antagonism) and the evidence base underpinning these. Possible future therapies are briefly discussed.

Entities:  

Keywords:  Raynaud’s phenomenon; critical ischaemia; digital ulceration; systemic sclerosis; treatment

Year:  2017        PMID： 29201156      PMCID： PMC5700788          DOI： 10.1177/1759720X17740074

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN： 1759-720X            Impact factor:   5.346


  76 in total

Review 1.  Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.

Authors:  J Pope; D Fenlon; A Thompson; B Shea; D Furst; G Wells; A Silman
Journal:  Cochrane Database Syst Rev       Date:  2000

2.  Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.

Authors:  B Coleiro; S E Marshall; C P Denton; K Howell; A Blann; K I Welsh; C M Black
Journal:  Rheumatology (Oxford)       Date:  2001-09       Impact factor: 7.580

3.  Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.

Authors:  D O'Reilly; L Taylor; K el-Hadidy; M I Jayson
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

4.  The incidence and natural history of Raynaud's phenomenon in the community.

Authors:  Lisa G Suter; Joanne M Murabito; David T Felson; Liana Fraenkel
Journal:  Arthritis Rheum       Date:  2005-04

5.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Authors:  J H Korn; M Mayes; M Matucci Cerinic; M Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; J R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; A Herrick; P A Merkel; R Simms; C P Denton; D Furst; N Nguyen; M Gaitonde; Carol Black
Journal:  Arthritis Rheum       Date:  2004-12

6.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors:  M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal:  Arthritis Rheum       Date:  1999-12

7.  The "distal-dorsal difference" as a possible predictor of secondary Raynaud's phenomenon.

Authors:  S Clark; S Hollis; F Campbell; T Moore; M Jayson; A Herrick
Journal:  J Rheumatol       Date:  1999-05       Impact factor: 4.666

8.  Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.

Authors:  A E Thompson; B Shea; V Welch; D Fenlon; J E Pope
Journal:  Arthritis Rheum       Date:  2001-08

Review 9.  Raynaud's phenomenon: a proposal for classification.

Authors:  E C LeRoy; T A Medsger
Journal:  Clin Exp Rheumatol       Date:  1992 Sep-Oct       Impact factor: 4.473

10.  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Authors:  Peter A Merkel; Karen Herlyn; Richard W Martin; Jennifer J Anderson; Maureen D Mayes; Patrice Bell; Joseph H Korn; Robert W Simms; Mary Ellen Csuka; Thomas A Medsger; Naomi F Rothfield; Michael H Ellman; David H Collier; Arthur Weinstein; Daniel E Furst; Sergio A Jiménez; Barbara White; James R Seibold; Fredrick M Wigley
Journal:  Arthritis Rheum       Date:  2002-09
View more
  9 in total

Review 1.  Raynaud's phenomenon.

Authors:  Ariane L Herrick
Journal:  J Scleroderma Relat Disord       Date:  2019-02-13

Review 2.  Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.

Authors:  Andreu Fernández-Codina; Esperanza Cañas-Ruano; Janet E Pope
Journal:  J Scleroderma Relat Disord       Date:  2019-01-28

Review 3.  Animal Models of Systemic Sclerosis: Using Nailfold Capillaroscopy as a Potential Tool to Evaluate Microcirculation and Microangiopathy: A Narrative Review.

Authors:  Angélica Mandujano; Melissa Golubov
Journal:  Life (Basel)       Date:  2022-05-08

4.  Digit Ulcerations in a Young Woman.

Authors:  Bibin Varghese; Erin Chew; Maximilian F Konig
Journal:  JAMA       Date:  2020-07-28       Impact factor: 157.335

5.  COVID-19-Induced Vestibular Neuritis, Hemi-Facial Spasms and Raynaud's Phenomenon: A Case Report.

Authors:  Rachana Vanaparthy; Srikrishna V Malayala; Mamtha Balla
Journal:  Cureus       Date:  2020-11-28

6.  A Real-World Experience of Mycophenolate Mofetil for Systemic Sclerosis: A Retrospective Multicenter Observational Study.

Authors:  Kyung-Ann Lee; Bo Young Kim; Sung Jae Choi; Seong-Kyu Kim; Sang-Hyon Kim; Hyun-Sook Kim
Journal:  Arch Rheumatol       Date:  2020-01-13       Impact factor: 1.472

Review 7.  Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies.

Authors:  Iqra Nawaz; Yashfa Nawaz; Eisha Nawaz; Muhammad Romail Manan; Adil Mahmood
Journal:  Cureus       Date:  2022-01-28

Review 8.  Raynaud's Phenomenon with Focus on Systemic Sclerosis.

Authors:  Magdalena Maciejewska; Mariusz Sikora; Cezary Maciejewski; Rosanna Alda-Malicka; Joanna Czuwara; Lidia Rudnicka
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.241

9.  Paraneoplastic Raynaud phenomenon associated with metastatic ovarian cancer: A case report and review of the literature.

Authors:  Tiffany S Lai; Man R Shim; David Shin; Mae Zakhour
Journal:  Gynecol Oncol Rep       Date:  2020-04-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.